Atlas Trials

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Clinical trial NCT03064763 · COMPLETED

Trial details

NCT number
NCT03064763
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Unresectable Stage IIIB-IV Malignant Melanoma
Start date
2017-03-07
Primary completion
2020-08-03
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.